Nizhpharm Group has started sales of Vildagliptin, a hypoglycemic agent for the treatment of type 2 diabetes. It is produced at the group’s site in Obninsk, the press service of Nizhpharm told GxP News.
“Vildagliptin has been added to Nizhpharm’s endocrinological portfolio, expanding the company’s range of generics with a DPP-4 inhibitor (gliptin)”, the press service said.
It is noted that during the commercial production of Vildagliptin tablets in Obninsk, dry granulation technology was used for the first time. This method “enhances the physico-chemical properties of the powders” and “streamlines the tablet manufacturing process.”
In Russia, the Federal Register of Diabetes shows over 5.2 million people are registered, with approximately 4.5 million having type 2 diabetes. More than 200,000 new cases of the disease are reported annually, according to Nizhpharm.
It should be noted that, according to the State Register of Medicines, Russia manufactures five drugs containing INN vildagliptin and five more drugs combining vildagliptin with metformin.